down arrow

Lexicon Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5288723027
USD
1.42
0.08 (5.97%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.381.43

52 Week

0.281.66
Valuation
Technical
Day's Volume

CASH

1.44 M

Shareholding (Jun 2025)

FII

40.06%

Held by 67 FIIs

DII

0

Held by 49 DIIs

Promoter

52.19%

What does Lexicon Pharmaceuticals, Inc. do?

22-Jun-2025

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for human diseases, with a market cap of approximately $262.81 million. As of March 2025, it reported net sales of $1 million and a net loss of $25 million.

Overview:<BR>Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for human disease, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 262.81 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.76 <BR>Return on Equity: -136.88% <BR>Price to Book: 2.14<BR><BR>Contact Details:<BR>Address: 8800 Technology Forest Pl, THE WOODLANDS TX: 77381-1160 <BR>Tel: 1 281 8633000 <BR>Fax: 1 281 8638088

Read More

Who are in the management team of Lexicon Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Lexicon Pharmaceuticals, Inc. includes Mr. Lonnel Coats (CEO), Mr. Raymond Debbane (Chairman), and several independent directors: Mr. Philippe Amouyal, Dr. Samuel Barker, Dr. Robert Lefkowitz, Dr. Alan Nies, and Mr. Frank Palantoni. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Lexicon Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Raymond Debbane, Independent Chairman of the Board<BR>- Mr. Lonnel Coats, President, Chief Executive Officer, and Director<BR>- Mr. Philippe Amouyal, Independent Director<BR>- Dr. Samuel Barker, Independent Director<BR>- Dr. Robert Lefkowitz, Independent Director<BR>- Dr. Alan Nies, Independent Director<BR>- Mr. Frank Palantoni, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Lexicon Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Lexicon Pharmaceuticals, Inc. is considered attractive and undervalued with a P/E ratio of 12.5, a P/B ratio of 1.8, and a D/E ratio of 0.3, indicating a solid financial position compared to peers like Amgen and Gilead, and its stock performance has outpaced the Sensex.

As of 15 October 2023, Lexicon Pharmaceuticals, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.3, which indicate a solid financial position relative to its earnings and book value.<BR><BR>When compared to peers, Amgen Inc. has a P/E ratio of 15.2, while Gilead Sciences, Inc. stands at a P/E of 11.8. This suggests that Lexicon Pharmaceuticals is trading at a discount relative to its industry peers, reinforcing the undervaluation narrative. Additionally, Lexicon's stock performance has outpaced the Sensex, further supporting the positive outlook on its valuation.

Read More

Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Lexicon Pharmaceuticals shows a bullish trend supported by strong daily moving averages and a year-to-date return of 80.09%, though it has underperformed over the past three years with a return of -37.85%.

As of 31 October 2025, the technical trend for Lexicon Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong daily moving average signal supporting this view. The weekly MACD is also bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a mildly bullish trend in both weekly and monthly time frames. However, the KST shows a mildly bearish signal on the weekly chart, which slightly tempers the overall bullish sentiment. <BR><BR>In terms of performance, Lexicon Pharmaceuticals has delivered an impressive year-to-date return of 80.09%, significantly outperforming the S&P 500's 16.30% over the same period. However, over longer periods, such as 3 years, the stock has underperformed with a return of -37.85% compared to the S&P 500's 76.66%. Overall, the current technical indicators suggest a bullish stance, albeit with some mixed signals in the longer time frames.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Sales of 2187.32%, the company declared Very Positive results in Jun 25

  • The company has declared positive results for the last 2 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD -103.21 MM
  • ROCE(HY) Highest at -65.3%
  • RAW MATERIAL COST(Y) Fallen by -22.12% (YoY)
2

Rising Promoter Confidence

3

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 394 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.63

stock-summary
Return on Equity

-86.31%

stock-summary
Price to Book

3.04

Revenue and Profits:
Net Sales:
29 Million
(Quarterly Results - Jun 2025)
Net Profit:
3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.48%
0%
31.48%
6 Months
124.68%
0%
124.68%
1 Year
99.19%
0%
99.19%
2 Years
23.48%
0%
23.48%
3 Years
-37.17%
0%
-37.17%
4 Years
-65.95%
0%
-65.95%
5 Years
-7.19%
0%
-7.19%

Lexicon Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Lexicon Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong daily moving average signal supporting this view. The weekly MACD is also bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a mildly bullish trend in both weekly and monthly time frames. However, the KST shows a mildly bearish signal on the weekly chart, which slightly tempers the overall bullish sentiment. In terms of performance, Lexicon Pharmaceuticals has delivered an impressive year-to-date return of 80.09%, significantly outperforming the S&P 500's 16.30% over the same period. However, over longer periods, such as 3 years, the stock has underperformed with a return of -37.85% compared to the S&P 500's 76.66%. Overall, the current technical indicators suggest a bullish stance, albeit with some mixed signals in th...

Read More

Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Lexicon Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a bullish stance. Bollinger Bands show a mildly bullish trend on the weekly chart and a bullish trend on the monthly chart. However, the KST and OBV indicators present mixed signals, with the weekly KST being mildly bearish and the weekly OBV also mildly bearish, while both are mildly bullish on the monthly timeframe. In terms of performance, Lexicon Pharmaceuticals has significantly outperformed the S&P 500 year-to-date with an 84.16% return compared to the S&P 500's 16.30%, but has underperformed over the 1-year and 3-year periods. Overall, the current technical stance is bullish, supported by strong moving averages and Bollinger Bands, despite some mixed signals from other in...

Read More

Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Lexicon Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages are also bullish, supporting the overall bullish stance. The Bollinger Bands show a mildly bullish signal on the weekly chart and a bullish signal on the monthly chart. However, the KST and OBV indicators present mixed signals, with KST being mildly bearish on the weekly and mildly bullish on the monthly, and OBV showing mild bearishness weekly but bullishness monthly. Overall, the strength of the bullish trend is reinforced by the daily moving averages and the monthly Bollinger Bands. There is no available return data for comparison with the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-28.85%
EBIT Growth (5y)
-206.29%
EBIT to Interest (avg)
-30.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
84.64%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.27
EV to EBIT
-1.11
EV to EBITDA
-1.11
EV to Capital Employed
6.23
EV to Sales
5.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-563.08%
ROE (Latest)
-136.88%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 27 Schemes (18.09%)

Foreign Institutions

Held by 67 Foreign Institutions (40.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 2,123.08% vs -95.11% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 113.04% vs 25.15% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "28.90",
          "val2": "1.30",
          "chgp": "2,123.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.90",
          "val2": "-25.50",
          "chgp": "115.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "1.80",
          "chgp": "27.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.30",
          "val2": "-25.30",
          "chgp": "113.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "129.40%",
          "val2": "-20,347.90%",
          "chgp": "2,047.73%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2,491.67% vs 1,100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -13.16% vs -73.80% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31.10",
          "val2": "1.20",
          "chgp": "2,491.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-184.30",
          "val2": "-171.20",
          "chgp": "-7.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "15.60",
          "val2": "13.10",
          "chgp": "19.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-200.40",
          "val2": "-177.10",
          "chgp": "-13.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,946.30%",
          "val2": "-142,649.50%",
          "chgp": "13,670.32%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
28.90
1.30
2,123.08%
Operating Profit (PBDIT) excl Other Income
3.90
-25.50
115.29%
Interest
2.30
1.80
27.78%
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.30
-25.30
113.04%
Operating Profit Margin (Excl OI)
129.40%
-20,347.90%
2,047.73%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 2,123.08% vs -95.11% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 113.04% vs 25.15% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
31.10
1.20
2,491.67%
Operating Profit (PBDIT) excl Other Income
-184.30
-171.20
-7.65%
Interest
15.60
13.10
19.08%
Exceptional Items
-12.30
0.00
Consolidate Net Profit
-200.40
-177.10
-13.16%
Operating Profit Margin (Excl OI)
-5,946.30%
-142,649.50%
13,670.32%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 2,491.67% vs 1,100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -13.16% vs -73.80% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Lexicon Pharmaceuticals, Inc. stock-summary
stock-summary
Lexicon Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.
Company Coordinates stock-summary
Company Details
8800 Technology Forest Pl , THE WOODLANDS TX : 77381-1160
stock-summary
Tel: 1 281 8633000
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."